Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delamanid + OBR in Children With MDR-TB
NCT03141060Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of delamanid in multidrug-resistant tuberculosis (MDR-TB) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of Participants With Adverse Events of >= Grade 3 Severity at Week 24, Percentage of Participants With Adverse Events of >= Grade 3 Assessed to be at Least Possibly Related to the Study Drug at Week 24 and 5 more. Started Feb 2019; status: completed.
02
Drugs
delamanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03141060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141060.